Practice Guideline

. 2024 Oct;51(12):3662-3679.

doi: 10.1007/s00259-024-06783-x. Epub 2024 Jun 20.

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Nathalie L Albert¹, Matthias Preusser², Tatjana Traub-Weidinger^{3

4}, Nelleke Tolboom^{5

6}, Ian Law⁷, Joshua D Palmer⁸, Eric Guedj⁹, Julia Furtner¹⁰, Francesco Fraioli¹¹, Raymond Y Huang¹², Derek R Johnson¹³, Christophe M Deroose¹⁴, Ken Herrmann¹⁵, Michael Vogelbaum¹⁶, Susan Chang¹⁷, Joerg-Christian Tonn¹⁸, Michael Weller¹⁹, Patrick Y Wen²⁰, Martin J van den Bent²¹, Antoine Verger²², Jana Ivanidze²³, Norbert Galldiks^{24

25

26}

Affiliations

¹ Department of Nuclear Medicine, LMU Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. nathalie.albert@med.uni-muenchen.de.
² Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
³ Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
⁴ Department of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria.
⁵ Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
⁶ Division Imaging & Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.
⁷ Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁸ Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁹ Institut Fresnel, Nuclear Medicine Department, APHM, CNRS, Timone Hospital, CERIMED, Aix Marseille Univ, Marseille, France.
¹⁰ Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.
¹¹ Institute of Nuclear Medicine, University College London (UCL), London, UK.
¹² Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
¹³ Department of Radiology, Mayo Clinic, Rochester, MN, USA.
¹⁴ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
¹⁵ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany.
¹⁶ Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA.
¹⁷ Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA.
¹⁸ Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
¹⁹ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
²⁰ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
²¹ Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
²² Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Université de Lorraine, Nancy, France.
²³ Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
²⁴ Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany.
²⁵ Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
²⁶ Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.

PMID: 38898354
PMCID: PMC11445317
DOI: 10.1007/s00259-024-06783-x

Practice Guideline

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Nathalie L Albert et al. Eur J Nucl Med Mol Imaging. 2024 Oct.

. 2024 Oct;51(12):3662-3679.

doi: 10.1007/s00259-024-06783-x. Epub 2024 Jun 20.

Authors

Affiliations

¹ Department of Nuclear Medicine, LMU Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. nathalie.albert@med.uni-muenchen.de.
² Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
³ Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
⁴ Department of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria.
⁵ Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
⁶ Division Imaging & Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.
⁷ Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁸ Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁹ Institut Fresnel, Nuclear Medicine Department, APHM, CNRS, Timone Hospital, CERIMED, Aix Marseille Univ, Marseille, France.
¹⁰ Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.
¹¹ Institute of Nuclear Medicine, University College London (UCL), London, UK.
¹² Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
¹³ Department of Radiology, Mayo Clinic, Rochester, MN, USA.
¹⁴ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
¹⁵ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany.
¹⁶ Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA.
¹⁷ Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA.
¹⁸ Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
¹⁹ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
²⁰ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
²¹ Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
²² Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Université de Lorraine, Nancy, France.
²³ Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
²⁴ Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany.
²⁵ Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
²⁶ Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.

PMID: 38898354
PMCID: PMC11445317
DOI: 10.1007/s00259-024-06783-x

Abstract

Purpose: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.

Methods: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).

Results: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.

Conclusion: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.

Keywords: DOTATATE; DOTATOC; Meningioma; PET; PRRT; Procedure guideline; SiTATE; Somatostatin receptor; Targeted radionuclide therapy; Theranostics.

PubMed Disclaimer

Conflict of interest statement

NLA has received honoraria for lectures, consultation or advisory board participation from Novartis, Advanced Accelerator Applications, Servier, OncLive and Telix Pharmaceuticals and research funding from Novocure.

MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape, OncLive.

AV has received honoraria for lectures and advisory board participation from Curium, Eisai and General Electrics.

CMD is/has been a consultant for: Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO. He has received travel fees from: GE Healthcare, Sirtex.

KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Fusion, personal fees from Immedica, personal fees from Onkowissen.de, personal fees from Novartis, personal fees from Molecular Partners, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen.

JCT has received research grants and honoraria for lectures, consultation or advisory board participation from the following for-profit companies: AAA-Novartis, Seagen, CarThera, Munich Surgical Imaging, Novocure.

PYW has received research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Celgene, Chimerix, Eli Lily, Erasca, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier, Vascular Biogenics, VBI Vaccines and honoraria for consultation or advisiory board participation from Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines.

JF has received honoraria for lectures and consultations from the following for-profit companies: Novartis, Seagen, Sanova, Servier.

JI has received research support from Novartis Pharmaceuticals (funds paid to institution, investigator-initiated trial grant).

RYH has received honoraria for consultation from Nuvation Bio, Servier and Telix, and honoraria for participiation in Scientific Advisory Boards from Vysioneer.

DRJ has received honoraria for consultation or advisory board participation from Novartis and Telix Pharmaceuticals.

EG has received honoraria for consultation or advisory board participation from Novartis.

JDP reports grants from the NIH and Genentech; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Varian Medical Systems, Novocure, ICOTEC; Travel support from Varian, ICOTEC; Participation on a Data Safety Monitoring Board or Advisory Board from Novocure.

MVDB has received honoraria for consultancy from Chimerix, Servier, Astra Zeneca, Boehringer-Ingelheim, Nerviano, Incyte, Biopharma, and Genenta.

NG has received honoraria for lectures from Blue Earth Diagnostics, and for advisory board participation from Telix Pharmaceuticals.

References

1. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620–7. 10.1002/(sici)1097-0215(19980529)76:5%3c620::aid-ijc2%3e3.0.co;2-s. - PubMed
1. Wangler C, Beyer L, Bartenstein P, Wangler B, Schirrmacher R, Lindner S. Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET. EJNMMI Radiopharm Chem. 2022;7:22. 10.1186/s41181-022-00176-x. - PMC - PubMed
1. Wang S, Yang W, Deng J, Zhang J, Ma F, Wang J. Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma. J Neurooncol. 2013;113:519–26. 10.1007/s11060-013-1146-y. - PubMed
1. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60:937–43. 10.2967/jnumed.118.230607. - PubMed
1. Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, et al. Comparison of (6)(8)Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2015;17:312–9. 10.1093/neuonc/nou131. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Affiliations

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources